These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25651422)

  • 1. Using digital polymerase chain reaction to detect minimal residual disease in myeloma by identifying FGFR3 up-regulation.
    McAuliffe S; Brown R; Catalano A; Ho PJ; Nassif N; Woodland N; Hart D; Weatherburn C; Yang S; Suen H; Paul C; Joshua D; Gibson J
    Leuk Lymphoma; 2015; 56(9):2714-6. PubMed ID: 25651422
    [No Abstract]   [Full Text] [Related]  

  • 2. Minimal residual disease monitoring in multiple myeloma.
    Davies FE; Rawstron AC; Owen RG; Morgan GJ
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):197-222. PubMed ID: 11987924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of minimal residual disease.
    Deptala A; Mayer SP
    Methods Cell Biol; 2001; 64():385-420. PubMed ID: 11070849
    [No Abstract]   [Full Text] [Related]  

  • 4. Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in myeloma.
    Compagno M; Mantoan B; Astolfi M; Boccadoro M; Ladetto M
    Methods Mol Med; 2005; 113():145-63. PubMed ID: 15968100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of self-quenched JH consensus primers for real-time quantitative PCR of IGH gene to minimal residual disease evaluation in multiple myeloma.
    Martinez-Lopez J; Martinez-Sanchez P; Garcia-Sanz R; Sarasquete ME; Ayala R; Gonzalez M; Bautista JM; Gonzalez D; San Miguel J; Garcia-Effron G; Lahuerta JJ
    J Mol Diagn; 2006 Jul; 8(3):364-70. PubMed ID: 16825510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium.
    Landgren O; Gormley N; Turley D; Owen RG; Rawstron A; Paiva B; Barnett D; Arroz M; Wallace P; Durie B; Yuan C; Dogan A; Stetler-Stevenson M; Marti GE
    Am J Hematol; 2014 Dec; 89(12):1159-60. PubMed ID: 25132630
    [No Abstract]   [Full Text] [Related]  

  • 7. [Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].
    Nihon Rinsho; 2016 Jul; 74 Suppl 5():565-9. PubMed ID: 30714704
    [No Abstract]   [Full Text] [Related]  

  • 8. Minimal residual disease detection in myeloma: no more molecular remissions?
    Rawstron AC
    Haematologica; 2005 Oct; 90(10):1300B. PubMed ID: 16219557
    [No Abstract]   [Full Text] [Related]  

  • 9. Detection of minimal residual disease in patients with multiple myeloma using clonotype-specific PCR primers designed from DNA extracted from archival bone marrow slides.
    Takamatsu H; Ogawa Y; Kobayashi N; Obata K; Narisawa T; Nakayama K; Munemoto S; Aoki G; Ohata K; Kumano Y; Ozaki J; Murata R; Kondo Y; Terasaki Y; Kurokawa T; Miyamoto T; Shimizu N; Fukushima T; Yoshida A; Ueda T; Yoshida T; Nakao S
    Exp Hematol; 2013 Oct; 41(10):894-902. PubMed ID: 23727584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative quantification of residual tumor cells by lightcycler real-time IgH PCR in autografted multiple myeloma patients.
    Rimelen V; Ferrand C; Debecker A; Sovalat H; Tancredi C; Eidenschenk A; Hénon P
    Leukemia; 2005 Mar; 19(3):492-5. PubMed ID: 15625553
    [No Abstract]   [Full Text] [Related]  

  • 11. Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma.
    Chandesris MO; Soulier J; Labaume S; Crinquette A; Repellini L; Chemin K; Malphettes M; Fieschi C; Asli B; Uzunhan Y; Fermand JP; Bories JC; Arnulf B
    Br J Haematol; 2007 Feb; 136(4):609-14. PubMed ID: 17223917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients.
    Vrabel D; Sedlarikova L; Besse L; Rihova L; Bezdekova R; Almasi M; Kubaczkova V; Brožová L; Jarkovsky J; Plonkova H; Jelinek T; Sandecka V; Stork M; Pour L; Sevcikova S; Hajek R
    Eur J Haematol; 2020 Mar; 104(3):190-197. PubMed ID: 31763708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of minimal residual disease in multiple myeloma and acute leukaemia.
    Bakkus MH; Juge-Morineau N; van der Werff ten Bosch JE
    Med Oncol; 1996 Jun; 13(2):121-31. PubMed ID: 9013476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and mutation status of candidate kinases in multiple myeloma.
    Claudio JO; Zhan F; Zhuang L; Khaja R; Zhu YX; Sivananthan K; Trudel S; Masih-Khan E; Fonseca R; Bergsagel PL; Scherer SW; Shaughnessy J; Stewart AK
    Leukemia; 2007 May; 21(5):1124-7. PubMed ID: 17344920
    [No Abstract]   [Full Text] [Related]  

  • 15. Improvement of clonality detection rate in multiple myeloma using fluorescent IgH PCR with different sets of primers.
    Welterlin V; Debecker A; Tschieb D; Zanetti C; Lange W; Hénon PR
    J Hematother Stem Cell Res; 2000 Dec; 9(6):983-91. PubMed ID: 11177613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGFR3 amplification in the absence of IGH@-FGFR3 fusion t(4;14) in myeloma.
    Quintero-Rivera F; El-Sabbagh Badr R; Rao PN
    Cancer Genet Cytogenet; 2009 Nov; 195(1):92-3. PubMed ID: 19837276
    [No Abstract]   [Full Text] [Related]  

  • 17. Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment.
    Nishihori T; Song J; Shain KH
    Curr Hematol Malig Rep; 2016 Apr; 11(2):118-26. PubMed ID: 26898557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal residual disease detection of myeloma using sequencing of immunoglobulin heavy chain gene VDJ regions.
    Ho C; Arcila ME
    Semin Hematol; 2018 Jan; 55(1):13-18. PubMed ID: 29759147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis.
    Soverini S; Terragna C; Testoni N; Ruggeri D; Tosi P; Zamagni E; Cellini C; Cavo M; Baccarani M; Tura S; Martinelli G
    Haematologica; 2002 Oct; 87(10):1036-40. PubMed ID: 12368157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial.
    Ho PJ; Brown RD; Spencer A; Jeffels M; Daniher D; Gibson J; Joshua DE
    Leuk Lymphoma; 2012 Sep; 53(9):1728-34. PubMed ID: 22329352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.